Pacira制药 PCRX 深 沪
已收盘 09-12 16:00:00 美东时间
27.12
+0.090
+0.33%
华盛通- 最 高27.46
- 今 开26.99
- 成交量 60.19万股
- 最 低 26.60
- 昨 收 27.03
- 总市值 12.56亿
- 52周最高 27.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.785
- 委 比 -37.14%
- 总股本 4630.47万
- 历史最高 121.95
- 量 比 1.09
- 振 幅 3.18%
- 历史最低 6.51
- 每 手 1
- 风险率 6.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Propanc Biopharma完成100万股普通股发行，每股4美元，筹资400万美元。股票于8月15日在纳斯达克上市，承销商为D. Boral Capital和Craft Capital Management。公司计划使用资金发展创新癌症疗法，旨在靶向癌症干细胞，尤其是胰腺、卵巢和结直肠癌。
08-19 12:30
Cleveland Browns Achieve True Circularity with PureFive™ Resin in Souvenir Cups
Cleveland Browns announce use of 100% PureFive™ resin in 2025 player souvenir cups, marking a circular plastics solution. The team, a PureZero partner with PureCycle, has worked since 2024 to improve recycling at games. The new cups, part of Churchill Container's 'Run It Back' line, feature PureCycle's innovative dissolution recycling technology, allowing up to 100% post-consumer recycled polypropylene while meeting food safety and performance st...
08-19 12:30
PharmaCorp Rx Inc. reports Q2 results
PharmaCorp Rx Inc. press release (TSXV:PCRX:CA): Q2 Net loss for the quarter reflects continued investment in corporate infrastructure and the catch-up of executive compensation deferred from 2024 Ope...
08-19 01:59
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Insights Ahead: Pacira BioSciences's Quarterly Earnings
Pacira BioSciences (NASDAQ:PCRX) will release its quarterly earnings report on ...
08-05 03:08
PharmaCorp Rx Inc. Files Annual Information Form to Boost Transparency
Pharmacorp Rx Inc. ( ($TSE:PCRX) ) has provided an announcement. PharmaCorp Rx ...
08-01 00:37
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced that it will report its second quarter financial results after U.S. markets close on August 5, 2025. A live conference call and webcast will follow at 4:30 p.m. ET. Listeners can pre-register for the call at [here](https://www.globenewswire.com/Tracker?data=-4-FMaMtMVB9iKXiohEMwJ1rMzwFpGSJ9r7tQQ-H0O2l3PRuCJPyGE2CKLtB__B_0PnXKbwBekvUWZ9A4K7HrQ9y1BfVPFKraVAB4pQhHee2hHIo6OqUh2IcEJi6180FJTtmuZFChm3EjF...
07-24 12:00
Pacira signs partnership with JNJ to expand Zilretta
Pacira BioSciences (NASDAQ:PCRX) said it has partnered with Johnson & Johnson MedTech (NYSE:JNJ) to enhance the availability of Zilretta, a treatment designed for knee pain caused by osteoarthritis. ...
07-22 20:52
Pacira BioSciences Collaborates With Johnson & Johnson MedTech To Expand Market Reach Of ZILRETTA, Leveraging Early Intervention Sales Force To Co-Promote Treatment To Existing And New Customers
Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient accessBRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the
07-22 20:03
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
Pacira BioSciences collaborates with Johnson & Johnson MedTech to expand ZILRETTA's market reach, targeting 7 million annual knee injections in the U.S. The partnership aims to increase sales calls and patient access, aligning with Pacira's 5x30 growth strategy. ZILRETTA, an extended-release treatment for osteoarthritis knee pain, leverages Johnson & Johnson's specialized sales force to extend its reach into sports medicine, pain management, and ...
07-22 12:00
